During the forecast period 2023 to 2033, the Isocitrate dehydrogenase (IDH) inhibitors Market is expected to grow at a value of 33% CAGR, according to Future Market Insights. By the year 2033, the global market for Isocitrate dehydrogenase (IDH) inhibitors is expected to rise up to a market valuation of US$ 39.16 Billion. Growth of the market can be attributed to increasing incidence of IDH-mutated cancers, such as acute myeloid leukemia (AML) and cholangiocarcinoma, which are commonly treated with IDH inhibitors.
Additionally, the development of more potent and selective IDH inhibitors, as well as the expansion of their use into other cancer types, is expected to further contribute to the growth of the market. Bayer and Agios Pharmaceuticals are among the key players in the IDH inhibitors market, with their respective drugs BAY 1436032 and ivosidenib being approved by the US FDA for the treatment of IDH-mutated cancers. These drugs have shown promising results in clinical trials, including high response rates and extended survival in patients with AML.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16847
The IDH inhibitors market is a rapidly growing field with significant potential for the treatment of several types of cancer. Continued research and development efforts, as well as the development of new drugs and treatment strategies, are expected to contribute to the growth of the market.
Key Takeaways from the Market Study
- The global Isocitrate dehydrogenase (IDH) inhibitors market is expected to grow with a 33% CAGR during 2023 to 2033.
- Oral route of administration is expected to hold 49% of the market share in 2023 for Isocitrate dehydrogenase (IDH) inhibitors market.
- North America is expected to possess 46% market share for Isocitrate dehydrogenase (IDH) inhibitors market in 2023.
- Europe Isocitrate dehydrogenase (IDH) inhibitors market size is expected to possess 43% market share in 2023.
“The development of combination therapies and alternative treatment strategies is being explored to further optimize the clinical benefit of IDH inhibitors. This, in turn, is fueling the growth of IDH inhibitors market.” states an FMI analyst
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-16847
Competitive Landscape:
Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.
- Bayer is collaborating with other pharmaceutical companies, such as Agios Pharmaceuticals, in the development of IDH inhibitors. The two companies have a joint development and commercialization agreement for ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme, which has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
- Agios’ Pharma lead IDH inhibitor candidate is ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme. Ivosidenib works by inhibiting the production of the oncometabolite 2-hydroxyglutarate (2-HG) and inducing differentiation of leukemia cells. Ivosidenib has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
Key Segments Profiled in the Isocitrate Dehydrogenase (IDH) Inhibitors Industry Survey
Type:
- IDH1 Mutant Medullary Malignant Tumor
- IDH2 Mutant Medullary Malignant Tumor
- Peptides
- Small Molecule
- Others
For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-16847
Molecule Types:
- Monoclonal Antibody
- Peptides
- Small Molecules
- Others
Route of Administration:
- Oral
- Parenteral
- Subcutaneous
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Use promo code >> FMITODAY to get flat 20% discount
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
